Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

March 1, 2022

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 43 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Mayra, and I'll be the conference operator for today's session. I'd like to welcome all of you to Cronos Group's 2021 Fourth Quarter and Full Year Earnings Conference Call. This call is being recorded today. At this point, I'll hand things over to Shayne Laidlaw from Investor Relations. Sir, the floor is yours.

Shayne Laidlaw

executive
#2

Thank you, Mayra. We appreciate everyone being here as we walk through Cronos Group’s financial and business results for the 2021 fourth quarter and the full year. With me today are Kurt Schmidt, our President and CEO; Bob Madore, our CFO; and Mike Gorenstein, our Executive Chairman. This morning Cronos Group put out a news release with these financial results, and it has been filed on our EDGAR and SEDAR profiles. You will also find this information, along with the prepared remarks, posted on our website in the Investor Relations section. Before handing the call to Kurt, I want to remind everyone that what we discuss on this conference call will include forward-looking statements. Those statements rest on assumptions subject to risks and uncertainties, and actual results could therefore differ materially from what the forward-looking statements project, including because of the factors set out in the cautionary statements and risk factors in the Company’s earnings release and regulatory filings, among them the Company’s most recent annual report on Form 10-K, which qualifies in their entirety any forward-looking statements made on this call. Also, on this call we may discuss certain financial measures that are not recognized under the U.S. Generally Accepted Accounting Principles, which the Securities and Exchange Commission refers to as non-GAAP measures.

Shayne Laidlaw

executive
#3

In our view, these non-GAAP metrics help management with planning, forecasting, and assessing business and financial performance, including how resources get allocated. You can find reconciliations of these non-GAAP measures to the most comparable reported GAAP measures in our earnings press release furnished to the SEC, which is accessible in the press room section of our website, thecronosgroup.com. These non-GAAP measures might not be comparable to measures other issuers use. I'd also like to mention that we are holding today's call from our respective remote locations. Because of that, brief delays, crosstalk, or minor technical issues may occur during this call. We thank you ahead of time for your patience and understanding. We will now deliver prepared remarks, and after that we will move into a question-and-answer session. With that, I'll hand things over to Cronos Group's President and CEO, Kurt Schmidt.

Kurt Schmidt

executive
#4

Thank you, Shayne, and good morning to all of you. We appreciate how patient you've been and that you're joining us for a second time in roughly two weeks. It's a pleasure to share with you our results for the 2021 fourth quarter and the full year, along with business updates. As I mentioned on our February 18th call, we began this year by carrying out a realignment of the business so that Cronos is positioned to drive profitable and sustainable long-term growth. That realignment places our products and our agility at the center. I see this realignment as having three distinct pillars. First, we've realigned the organization, removing redundancy and centralizing functions under common leadership. Second, we're reducing complexity and continuing with our asset-light model. As part of that, we've decided to exit the Peace Naturals Campus. I'll say more about these plans in a minute. We're also continuing to perform product reviews and pricing optimization scenarios across our brands and products. And finally, we've implemented a cost reduction initiative, expected to reduce operating expenses by approximately $20 million to $25 million in 2022. When we spoke two weeks ago, we brought you updates primarily on the first and third pillars of our realignment initiative. Today, we'd like to provide a further development on the second pillar.

Kurt Schmidt

executive
#5

In our earnings release this morning, we said that we're exiting the Peace Naturals Campus in Stayner, Ontario. A great deal of analysis went into making this call. And although we recognize it will bring transition and change, we also recognize it's the correct call to help secure Cronos' long-term growth. Operating an asset-light business has always been our aim, with a focus on brands and R&D. This transition brings us in line with that vision. We've long held that as the industry matures, cultivation would move to large scale agricultural specialists, which is why we concentrated on establishing joint ventures and partnerships worldwide with best-in-class offers. We now feel confident that the industry and our supply chain in Canada have reached a maturity level at which we can put this approach into practice. We have consistently aimed for a diverse supply chain, supported by contract manufacturers and third-party producers to supplement our cultivation and manufacturing needs. Beyond building those relationships over many years, we have been developing capabilities with our JV partner, Cronos GrowCo, in order to execute this move. We are very pleased with their premium flower cultivation, which has increasingly become an important component to our biomass supply. We know their capabilities and efficient downstream processing will enable our goal of improved profitability.

Kurt Schmidt

executive
#6

Safeguarding our top-line expansion and keeping R&D momentum going matters enormously to the strategy we're pursuing ahead, and those rank as the leading priorities for this transition. To make sure things run smoothly, Cronos will keep operating the Peace Naturals Campus, winding down and shifting activities in stages across 2022, with the exit planned for the close of 2022. Beyond that, our attention is on preserving the ties we have with Canadian customers. Our plan is to secure a sales license from Health Canada at GrowCo's facility so that continuity holds. As for R&D, every initiative will move forward as scheduled at our various sites. This transition will involve plenty of moving parts and complexities to handle. Still, we're concentrating on adhering as closely as we can to our timeline, while keeping our focus on revenue growth and launching innovative products into the market. We feel grateful toward our Stayner associates for their dedication and their contributions to Cronos Group. And we thank the associates who keep working at our Peace Naturals Campus to deliver a seamless exit from the facility over the course of this year. Now I'd like to move to our business and take you through a few highlights from the fourth quarter and the full year 2021.

Kurt Schmidt

executive
#7

This year certainly came with difficulties, yet we should also recognize our successes. All the foundational effort we’ve invested to build our brands and succeed with consumers is now becoming visible in our results. In Canada, the Spinach brand keeps gaining ground. During the fourth quarter, SOURZ by Spinach gummies further solidified a market share in the category that remains in the double digits. Nationally in the edibles category, all three SOURZ by Spinach flavors ranked among the top 10, and in Ontario, Blue Raspberry sits in the number one position. For Spinach in the flower category, our market share finished the quarter in the high-single-digits. That strength in flower stems from years of R&D focused on breeding and genetics. Notably, we have provided GrowCo with a great deal of that genetics and look forward to helping them keep elevating their flower portfolio over time. We also introduced our sub brand, Spinach FEELZ, created to deliver distinctive and enhanced experiences, enabled by proprietary blends of rare cannabinoids together with more common cannabinoids such as THC and CBD, across a wide variety of products and formats. In October 2021, we launched our first cultured cannabinoid products under Spinach FEELZ, the Chill Bliss gummy, which is making considerable progress within the edibles category.

Kurt Schmidt

executive
#8

And even though our base launch using cultured CBG is at an early stage, the trends have us feeling good. What our Spinach brands and products have achieved so far shows what happens when you get the fundamentals right. We'll keep putting money into innovation so we can give consumers the products they want, plus others they haven't even imagined yet. With Spinach, we're beginning to see things work in the Canadian market, and we're waiting for the chance ourselves to apply our innovation and the key things we've learned in the market to other markets as they open up. As we restructure the organization to fit our go-forward strategy, most of our energy will go toward elevating our brands through rare cannabinoids and a focus on adult-use products. The Canadian market has always been the region we use to fine tune our innovation and product development work. Most of our adult-use products reach consumers in Canada, yet we keep doing extensive consumer insights work across every region where we operate, with an eye toward adult-use in the United States. The United States stays a great place to learn more about how consumer preferences evolve, while we concentrate on building those turnkey solutions in the markets where we operate today.

Kurt Schmidt

executive
#9

Now, on Israel — we remain very pleased with how our medical business is performing. Our Peace Naturals brand began reaching medical patients via participating pharmacies during Q2 of 2020. Distribution now extends to nearly every pharmacy that dispenses medical cannabis, and we'll keep growing it as additional pharmacies come on line. The total number of patients in Israel has risen considerably as well, reaching roughly 190,000 — a 40% gain compared with the same period a year earlier — and there's a long runway for further growth. Following the recent survey run by Cannabis Magazine that named Peace Naturals the most recognized cannabis brand in Israel, there's plenty to look forward to as we strive to satisfy patient demand in this market. In light of our business's growth, we've begun devoting time to digging deeper into the Israeli market and how we can position ourselves as a leader there. Israel's population stands at just over 9 million people, and it holds one of the highest cannabis usage rates worldwide. In contrast to North America's cannabis market, Israel faces far less competition from illicit markets, thanks to its stringent border controls and security infrastructure. The swift expansion of Israel's medical market brings to mind the early days of Canada's medical market, when demand exceeded supply and the stigma attached to the product was rapidly fading.

Kurt Schmidt

executive
#10

Given our production capabilities, the local team we’ve built, and a solid lineup of branded products, we’re in a strong position to win in Israel. As we restructure the company around our forward-looking strategy, most of our effort will go toward lifting our brands through rare cannabinoids and concentrating on adult-use offerings. To close, I’d like to lay out four central business priorities, each aimed at pushing initiatives that fit our vision and are built to produce sustainable growth. For 2022, first, we aim to speed up growth by concentrating on the core business, using our best-selling items to realize each brand’s potential, while staying disciplined about how we invest our time and resources and about which opportunities we think will generate the biggest returns. Second, we’ll carefully assess our manufacturing approaches so that we proceed only with new products and processes that deliver added value and support our strategic vision. Third, we’ll build a strong innovation platform across Cronos’ group portfolio of global brands, grounded in our conviction that rare cannabinoids will create differentiation. Fourth, we’ll keep entering the U.S. market as our North Star by controlling internal capital spending and external capital allocation so we retain the flexibility to seize opportunities that will make Cronos a leader in the U.S.

Kurt Schmidt

executive
#11

We still have plenty of work in front of us on that front, but I am confident that the steps we laid out today will strengthen our business and position us to succeed over the long term. With that, I will hand things over to Bob Madore, our CFO.

Bob Madore

executive
#12

Thanks, Kurt, and good morning, everyone. Before we get into the financial results, let me give you some more detail on our planned exit from the Peace Naturals Campus. Because of the Company's planned exit from the Peace Naturals Campus, the Company incurred a $119.9 million noncash impairment charge on long-lived assets in the fourth quarter of 2021. The Company also expects to incur charges of approximately $4.5 million in connection with the planned exit, and all of these impact the ROW segment. Those charges include employee-related costs, such as severance, relocation and other termination benefits, as well as contract termination and other related costs, which are expected to be incurred primarily in the second half of 2022. The Company also anticipates capital expenditures of approximately $2.5 million to modernize information technology systems and build distribution capabilities. Cronos Group looks forward to leveraging GrowCo's capabilities in premium flower cultivation and efficient downstream processing, with the intention to improve profitability of the Company's Canadian operations. In addition to further leveraging its joint venture with GrowCo, Cronos Group will continue to maintain a network of third-party licensed processors to supplement cultivation and manufacturing needs. Now, let's get into the financial results filed today.

Bob Madore

executive
#13

For 2021 overall, consolidated revenue rose 59% compared with the prior year, reaching $74.4 million, and the rest of the world segment performed strongly, led by Canada and Israel. Net revenue in that rest of the world segment came to $64.6 million for 2021, up 73% year-over-year. The United States segment grew 4% versus the prior year, to $9.9 million. Given the slower growth in the U.S., we are committed to rightsizing that segment so it aligns with our go-forward strategy, with emphasis on improving profitability. Moving now to results for the fourth quarter of 2021: the Company reported consolidated net revenue of $25.8 million for Q4 2021, which was 51% higher than the same period a year earlier. The year-over-year revenue growth came mainly from continued expansion in the Canadian adult-use market and higher sales in Israel's medical market. Consolidated gross profit for Q4 2021 was $1.9 million, an improvement of $16.8 million compared with the fourth quarter of 2020. That gain over the prior year was driven mainly by lower inventory write downs and higher gross profit in the rest of the world segment. Consolidated adjusted EBITDA for the fourth quarter of 2021 was negative $27.4 million, an improvement of $25.8 million versus the fourth quarter of 2020.

Bob Madore

executive
#14

The year-over-year gain came mainly from better gross profit plus lower sales and marketing and research and development expenses. Now for our reporting segments. For the rest of the world segment, net revenue in the fourth quarter of 2021 came in at $22.7 million, up 68% from the same period a year earlier. That year-over-year revenue growth was mainly due to gains in both adult-use extracts in flower categories in Canada and sales in the Israeli medical market. Gross profit for the rest of the world segment in the fourth quarter of 2021 was $2.4 million, which is a $19.1 million improvement over the fourth quarter of 2020. That improvement against the prior year was mainly due to fewer inventory write downs and higher sales volume of cannabis extracts in the Canadian market, which carries a higher gross profit than other product categories. Adjusted EBITDA for the rest of the world segment in the fourth quarter of 2021 was negative $14.6 million, which is a $21.8 million improvement over the fourth quarter of 2020. That improvement against the prior year was mainly due to better gross profit and lower research and development expenses.

Bob Madore

executive
#15

Now shifting to the U.S. segment. For the fourth quarter of 2021, net revenue came in at $3.1 million, which is an 11% drop compared with the same period a year earlier. That year-over-year decrease resulted from lower volume stemming from competitive pressures. About two weeks ago, we discussed at length that the U.S. CBD business is not performing as we would like. Our strategic review of this business — encompassing possible price optimization, SKU rationalization, and changes to distribution channels — continues to be a leading priority, and we plan to provide meaningful updates when the timing is right. Gross profit for the U.S. segment in the fourth quarter of 2021 was negative $0.5 million, a $2.3 million decrease versus the fourth quarter of 2020. That year-over-year drop was mainly attributable to higher production costs as well as greater inventory valuation adjustments reflecting net realizable value. Adjusted EBITDA for the U.S. segment in the fourth quarter of 2021 was negative $8.3 million, an improvement of $3.5 million compared with the fourth quarter of 2020. The improvement relative to <<inaudible>> sales and marketing, and general and administrative expenses. Now moving to the balance sheet. The Company closed the quarter with roughly $1 billion in cash and short-term investments, down about $35 million from the third quarter of 2021.

Bob Madore

executive
#16

For the quarter, capital expenditures came in at $0.6 million, and the spending emphasis was on our strategic priorities worldwide. Compared with a year earlier, capex is down roughly 95%, a decline caused by lower outlays on enterprise resource planning implementation and on capital improvements at our facilities. Our commitment to deploying capital in a disciplined way remains intact, and we will do so only where it fits with our strategic priorities. Finally, I want to update you on the remediation work tied to the material weakness we disclosed last quarter. As a company, we are committed to adopting best practices for financial reporting. Management, with the audit committee providing oversight, has put a plan in place that we are working hard to phase in over the course of 2022. I’m also pleased to report that the material weaknesses previously disclosed concerning inventory verification have been remediated. With that, I’ll hand it back to Kurt.

Kurt Schmidt

executive
#17

Thank you, Bob. We're well aware that the difficulties we've faced lately have been drawing attention away from what we've achieved. What I'd like you to take away today is this: in spite of everything, you're beginning to witness our strategy and execution reflected in the numbers. Through Spinach, we're establishing a strong brand in Canada and have shown market share gains that are sustainable. In Israel, a solid medical market, we're experiencing tremendous growth. Winning that market took a lot of hard work. We're taking steps to realign the organization and acting fast to help the business improve through efficiencies and profitability amid markets that are shifting rapidly. No other company has brought a cultured cannabinoid product to market using breakthrough science and technology—we're the first. And when it comes to marketing rare cannabinoids in a manner that connects with consumers, we lead the way. We're headed in the right direction, and we're meeting the challenges that lie ahead. With that, I'll open the line for questions.

Operator

operator
#18

Andrew Carter from Stifel is up first with our opening question.

Andrew Carter

analyst
#19

Hey there, thanks, and good morning. The first thing I'd like to ask is: how long has the potential exit of Stayner been under consideration as a way to kind of preserve capital? And also, in terms of generating some of those redundancies — with the redundancies, because my thinking is that you wouldn't want to risk slowing the revenue momentum. So maybe you could just walk us through that? Thanks.

Kurt Schmidt

executive
#20

Yes, this is Kurt. This has been underway for quite a long while. Again, the entire concept, the whole GrowCo initiative, stemmed from our conviction that cultivation will shift toward the agricultural sector. That is why we set up the GrowCo JV at the outset, and we are proving that out. So, across construction, start-up, and follow-up, we have reached every milestone we aimed for. So, that has been ongoing for a while. And we are very happy with where we stand right now. We are delivering high quality and well priced cannabis through the GrowCo supply chain. And we have sufficient redundancies within our supply chain, as we mentioned in the upfront remarks, that we feel very good, but this is the right moment for this move.

Andrew Carter

analyst
#21

And then, just briefly, if I could turn to the revenue momentum. It was great in the quarter, and it’s been a great build for the edibles brand; the Spinach brand has really stood out. We just released the headset data for February this morning. It has taken a step back, for both the edible and the Spinach. Is that something you see as seasonality? Anything you’re seeing in terms of reduced shipments? And could Canadian adult-use revenue take a step back sequentially here in the calendar first quarter? Thanks.

Kurt Schmidt

executive
#22

Yeah, I’d say some of that is a bit of seasonality, plus a temporary resurgence of COVID in the first quarter that caused some disruption. Still, on the whole, I think the momentum we saw in the first quarter was pretty positive. And the world is returning to normal in the second quarter, I believe. So we expect that to correct itself. We feel very confident about how Spinach is progressing on the consumer side.

Operator

operator
#23

The next person to ask a question is Rahul Sarugaser, who's calling in from Raymond James.

Michael Freeman

analyst
#24

Hello. Good morning to Kurt, Bob, and Shayne. Michael Freeman here, filling in for Rahul Sarugaser this morning. I’ve got one question. First, regarding the downstream impact of the exit from the Peace Naturals site, I suppose. Could you lay out for us what this means for headcount, where your top-notch R&D facilities may be relocating as part of this move, and then the wider effects on the cost structure as you work through the exit through 2022?

Kurt Schmidt

executive
#25

All right, there are three items to address there. The first is — I won't give a precise headcount figure. But without question, as this facility gets shut down, there will be shifts in how large the organization is. There's no doubt about that. At the same time, we're equally — we're strongly committed, and we've carefully planned this to make sure our employees are treated properly. And we carry this out in a high-quality manner as we work through the process. Still, it will result in a smaller Stayner facility, including a reduction in how many employees we have. The second one, on R&D, it's important to keep in mind that we have several facilities throughout the supply chain where the R&D operates. Winnipeg has a facility, and we already work there. Eventually we'll move some things into GrowCo, and this has no impact on our R&D scope. So, as we've discussed, our key driver is brands and R&D. And R&D centers on margin-accretive innovation and winning in rares, and we'll see no impact. There will be no effect on the innovation we're developing and the timelines we're driving toward. Then your third one, I believe, was about margin profile and the business process.

Kurt Schmidt

executive
#26

We aren’t providing specific guidance. Still, clearly, in making this decision, we clearly see a substantial chance to demonstrate that our business can be profitable. The Peace Naturals Campus comes with genuinely heavy complexity and a heavy overhead burden. So taking that out of our cost structure, right, together with lower production costs and more efficient downstream processing at GrowCo, which are cultivation experts, we think there is a significant opportunity to grow gross profit in both dollar and percentage terms. And remember, you have to pair that with the — during our third quarter earnings call, when we announced the first phase of the restructuring, which will cut operating costs by between $20 million and $25 million. So we believe all these initiatives place us on a really strong path, improving profitability, while keeping our clear focus on two very important things, which are margin and accretive innovation, winning in rares, and of course, sustainable growth and building our brands, particularly Spinach.

Michael Freeman

analyst
#27

My follow-up is probably for Bob. Starting in the third quarter, we saw some impairments tied to the Ginkgo exclusives license. And those show up once more in the 4Q financials. So I was hoping you could unpack those impairments and maybe connect them to how you value those licenses specific to Ginkgo. Thanks.

Bob Madore

executive
#28

Yes. One of the larger difficulties when pursuing the rare cannabinoids and hitting the various milestones is that, under accounting rules — and I won't put everybody to sleep with the details, but with that kind of valuation methodology, the relief-from-royalty approach — in an area where you truly lack any track record, any operational history, and from a projection standpoint, you're really sort of constrained, somewhat handcuffed in the valuation exercise, and in the growth level you're able to build into those projections, purely from a valuation standpoint. These valuations don't reflect the commercial opportunities that we believe developing these rares holds for us. It's simply a consequence of heavily discounting future projections in a space that is very new, rarefied air. Over time, as we gain more experience and history commercializing the opportunities, as we develop additional rares — we have six more milestones ahead of us beyond the two already completed — we believe that commercialization track record, what the market represents, and improved visibility into it will assist with that valuation exercise, but it is in no way what we believe it's worth, what we believe we could sell it for to a third party, if we chose to, which we don't.

Bob Madore

executive
#29

This is simply a consequence related to how accounting valuation methods work.

Operator

operator
#30

The next person to ask something is John Zamparo of CIBC.

John Zamparo

analyst
#31

Let me begin with GrowCo. Roughly what share of your present sales—whether for Q1 so far or for Q4—is coming from GrowCo? And could you remind us of the terms under which you buy from the JV? Do you pay fair market value, or does that arrangement include some kind of discount?

Bob Madore

executive
#32

Yes. So we truly began making our initial GrowCo purchases back in 2021. Before that, the volume was fairly modest — our Stayner facility wasn't able to meet all of our supply and demand needs. So besides GrowCo, which has really only been operating for the last 8 to 12-month period of time, we relied on other third-party cultivators as well to cover our biomass and dry flower requirements. Now, going forward, we clearly want to build on GrowCo's success with the harvest they've already completed and source considerably more from them. On pricing, it's competitive market pricing, relatively speaking, but far more efficient, effective and lower cost than what producing it ourselves internally used to cost us. That's the reason behind this morning's announcement regarding Stayner. We simply believe that large agri growers like GrowCo are where we always kind of thought the action would be and the most effective and efficient way of doing things in the future — we feel we've picked one of the best partners available. So we're excited about the opportunity.

John Zamparo

analyst
#33

My second question concerns Israel. Stepping back, how do you see that country developing over time? Will Canadian producers keep supplying the entire market, or do you expect it eventually to become a domestically supplied market? I realize you have some exposure via Cronos Israel should that moment arrive, but I would appreciate hearing your view on how that market will evolve.

Kurt Schmidt

executive
#34

Honestly, a great deal hinges on what happens with regulation in Israel. At present, the approach we take — and this applies across everything we do — is that our cultivation has plenty of built-in redundancy. We bring product in from Canada, we grow it ourselves through our own cultivation via our joint venture on the converse, and we also purchase from third-party suppliers based in Israel. That leaves us very well resourced. In our view, the market itself will be the main driver as it keeps expanding and maturing. Demand is clearly rising, and we believe we are fully — we are positioned well to expand alongside that demand. So in our minds, we sit in a very strong position.

Operator

operator
#35

Gaurav Jain with Barclays has our next question.

Gaurav Jain

analyst
#36

You've posted a $27 million EBITDA loss for this quarter. Is it reasonable to think that nearly 80% of that loss sits in the U.S. segment, while 20% falls in the rest of world segment?

Bob Madore

executive
#37

My apologies—would you mind saying that final sentence again, specifically the percentages you mentioned?

Gaurav Jain

analyst
#38

Regarding that $27 million figure, would it be reasonable to think that roughly $20 million of the loss falls within the U.S. segment, while $8 million lands in the rest of the world segment?

Bob Madore

executive
#39

Yes, we do split out EBITDA losses at that level.

Gaurav Jain

analyst
#40

Alright, so I suppose what I'm after here is this: regarding your U.S. business, you made a remark about rightsizing it — that it isn't where it should be. I mean, you've said that repeatedly over, I'd say, the past couple of years, and even so, that business does just $10 million in sales. What's your plan to fix it?

Bob Madore

executive
#41

Regarding that strategic alignment piece — please continue, Kurt.

Kurt Schmidt

executive
#42

Yes. Well, obviously, we're not pleased. We're examining — we continue to believe — those brands still have considerable strength. One area we'll be concentrating on more, as we mentioned before, is the adult-use portion of the business. We're working through that right now. We just announced the leadership on the last earnings call, which took place only two weeks ago. So, that's underway. The strategic review is still ongoing. That being said, we'll reach the right conclusions as we move forward. But again, those brands still hold strength, they still connect with people. And that's what we're focused on. We're simply not prepared to announce anything yet. We'll do so once we get closer.

Gaurav Jain

analyst
#43

Moving on to my next question — when I look at your market cap of roughly $1.3 million and net cash of about $1 billion, how should we think about Cronos? For instance, would you deploy that $1 billion into areas beyond cannabis where you could create economic value, since you and all your peers, I believe, are dealing with the same problem that cannabis operations have been rather weak? So, would you consider something outside that business?

Kurt Schmidt

executive
#44

I'll also bring in Mike, our Chairman, since he's the one heading this up. Well, what — everything we announced today centers on brands and on expanding the business. It's been a focal point and the center of attention for the U.S. And providing us the financial — you're correct, we have a fairly solid balance sheet allowing us to make those sorts of investments we want to make — potentially ones we can make in the U.S., which Mike has actually been spearheading for us. A good illustration is PharmaCann. They announced just this morning that they closed on their LivWell acquisition. And the reason we put money into PharmaCann was the confidence we hold in their management and their capacity to grow strategically both organically and through M&A. You're seeing that. And we have a partnership with them. And this is the type of investment our balance sheet lets us make. Mike, I don't know if you'd like to add anything to this.

Mike Gorenstein

executive
#45

Absolutely, Kurt. Appreciate it. So our thinking is around putting capital into things we believe can deliver a strong ROI on a global basis over time. Take Spinach SOURZ, rare cannabinoids, the FEELZ line — as markets open, we'll be positioned to bring those products in when adult-use launches. What we've invested in Canada, we don't view as Canada in isolation, but rather how do you take those and — you're seeing the performance go head to head with the top U.S. brands, with other Canadian brands in Canada — transitioning them into markets such as Israel and the U.S. as they open. Beyond that, we're looking at opportunities for brands or IP that we see in other markets, or infrastructure distribution partners in the U.S.

Operator

operator
#46

The next person to ask something is Andrew Bond <<inaudible>> with Jefferies.

Andrew Bond

analyst
#47

Hello there, and good morning. This is Andrew Bond speaking on behalf of Owen Bennett. We appreciate you taking the time to address our questions. So perhaps we could explore Israel a bit more thoroughly — I realize we've covered this ground previously, but let's focus on the nearer term. I'd like to hear what you anticipate regarding how the robust momentum observed during the third and fourth quarters could carry forward. Maybe there's some durability to be found with the Peace Naturals brand. Thus, I was hoping to hear your perspective on the ways Cronos would hold an edge over rival LPs that sell into Israel, and what framework we ought to use when considering that momentum going forward as we head into 2022? Thank you.

Kurt Schmidt

executive
#48

I believe our momentum is strong right now. As we've discussed, the market itself is performing very well. We expect that to keep going as additional pharmacies join and more patients enter medical cannabis, so that's a powerful driver for us. We believe we hold a competitive edge, since we have an excellent portfolio of brands and we address every segment that matters. As I mentioned, we were rated the top brand in Israel. Plus, we have a terrific team operating locally. So we have our own people on the ground, and they're excelling at sales and marketing, at customer relationships, and at building doctor relationships in the market. So we feel our local organization is very strong, backed by excellent brands. And lastly, we spoke about our capacity to serve the market. We're very well positioned for that. We follow the same type of approach we applied in Canada. And we can do it through the joint venture, through third parties, and through what we do in Canada. So we believe we're well positioned on that front. And once more, this is simply a market where we foresee strong momentum as the New Year begins, and we see nothing standing in our way.

Kurt Schmidt

executive
#49

The key is staying focused on creating excellent brands and excellent products. Not only is Peace Naturals very highly rated, but many of our products also rank highly among the most prescribed products.

Operator

operator
#50

Up next, we have a question from Michael Lavery, who is with Piper Sandler.

Michael Lavery

analyst
#51

Thanks. Morning, everyone. Apologies for coming in a bit behind schedule. I realize this may echo what's already been asked, but could you bring us up to speed on where things stand with Altria? And in what ways — whether or not that connection could be useful for your U.S. operations — are there any opportunities you see there?

Kurt Schmidt

executive
#52

So, Altria is a strategic investor in the Company. They hold Board seats there. They're represented on the Board. And once again, they've been terrific in backing us as we build out our business. When it comes to the U.S., one thing we've done is the PharmaCann investments. So that is — that's a strong illustration of the strength we get from the whole Board, with both of our independents represented from GGP and, naturally, Altria.

Michael Lavery

analyst
#53

Could you also perhaps share an update on edibles and tell us how the FEELZ brand is performing?

Kurt Schmidt

executive
#54

Right. That topic came up already. Yes. Things are going great with the FEELZ brand. As we mentioned, based on Hifyre data, we’re still holding a double-digit share of the edibles market through the fourth quarter. We’re seeing continued growth in 2022. Within our SOURZ lineup, there are three products in that line. According to LCS data, they rank among the top 10. So our performance is extremely strong. And as we noted, in October, we launched — under Spinach, we launched the FEELZ edibles, which are our first rare cannabinoids using CBG and THC. And the progress — it’s early progress, but we’re really happy with how that’s developing. And in addition to that, we also launched our first rare cannabinoid-based product with CBG. That happened in January.

Operator

operator
#55

That wraps up the Q&A — we have no more questions. This brings today's conference to an end. We appreciate everyone joining us. You're welcome to disconnect at this point. Have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.